Artificial Pancreas (AP) is an expression referred to a set of techniques for the closed-loop control of the plasma glucose concentration by means of exogenous insulin administration in diabetic patients. Diabetes comprises a group of metabolic disorders characterized by high blood sugar levels over a prolonged period, due to pancreas failure to produce enough insulin and/or insulin resistance, so that higher amounts of insulin are usually required in order to keep glycemia in a safe range. In this work, we face the problem of glucose control for a class of Type-2 diabetic patients, in the presence of sampled glucose measurements and without any information about the time course of insulinemia. A compact physiological model of the glucose-insulin system is reviewed, then an observer (based on this model) is designed to estimate the insulin trajectory from the glucose samples. Finally, a feedback control law (based on the reconstructed state) is designed to deliver exogenous intra-venous insulin to each individual. Simulations have been performed in-silico on models of virtual patients, whose parameters are tuned according to real data, and aim at validating the method in the presence of parameter variations and quantization errors.
Sampled-data observer-based glucose control for the artificial pancreas
Borri A;Palumbo P;Manes C;Panunzi S;De Gaetano A
2017
Abstract
Artificial Pancreas (AP) is an expression referred to a set of techniques for the closed-loop control of the plasma glucose concentration by means of exogenous insulin administration in diabetic patients. Diabetes comprises a group of metabolic disorders characterized by high blood sugar levels over a prolonged period, due to pancreas failure to produce enough insulin and/or insulin resistance, so that higher amounts of insulin are usually required in order to keep glycemia in a safe range. In this work, we face the problem of glucose control for a class of Type-2 diabetic patients, in the presence of sampled glucose measurements and without any information about the time course of insulinemia. A compact physiological model of the glucose-insulin system is reviewed, then an observer (based on this model) is designed to estimate the insulin trajectory from the glucose samples. Finally, a feedback control law (based on the reconstructed state) is designed to deliver exogenous intra-venous insulin to each individual. Simulations have been performed in-silico on models of virtual patients, whose parameters are tuned according to real data, and aim at validating the method in the presence of parameter variations and quantization errors.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.